Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-Clinical Therapeutic Approaches Publisher Pubmed



Sheibani M1 ; Azizi Y2, 3 ; Shayan M4, 5 ; Nezamoleslami S4 ; Eslami F4, 5 ; Farjoo MH6 ; Dehpour AR4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  2. 2. Physiology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  3. 3. Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran
  5. 5. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Source: Cardiovascular Toxicology Published:2022


Abstract

Doxorubicin is an effective chemotherapeutic agent prescribed to treat solid tumors (e.g., ovary, breast, and gastrointestinal cancers). This anti-cancer drug has various side effects, such as allergic reactions, cardiac damage, hair loss, bone marrow suppression, vomiting, and bladder irritation. The most dangerous side effect of doxorubicin is cardiomyopathy, leading to congestive heart failure. The exact mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood. Alteration in myocardial structure and functional cardiac disorders is provoked by doxorubicin administration; subsequently, cardiomyopathy and congestive heart failure can occur. Congestive heart failure due to doxorubicin is associated with mortality and morbidity. Probably, doxorubicin-induced cardiotoxicity starts from myocardial cell injury and is followed by left ventricular dysfunction. Many factors and multiple pathways are responsible for the creation of doxorubicin-induced cardiotoxicity. Inflammatory cytokines, oxidative stress pathways, mitochondrial damage, intracellular Ca2+ overload, iron-free radical production, DNA, and myocyte membrane injuries have critical roles in the pathophysiology of doxorubicin-induced cardiotoxicity. Unfortunately, there are currently a few medications for the treatment of doxorubicin-induced cardiotoxicity in clinical settings. Extensive basic and clinical researches have been carried out to discover preventive treatments. This review briefly discusses the basic and experimental approaches for treating or preventing doxorubicin-mediated cardiotoxicity based on its pathophysiological mechanisms. © 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Other Related Docs
12. A Comprehensive Insight Into the Anti-Inflammatory Properties of Dapsone, Naunyn-Schmiedeberg's Archives of Pharmacology (2022)
20. Melatonin for Gastric Cancer Treatment: Where Do We Stand?, Naunyn-Schmiedeberg's Archives of Pharmacology (2025)
22. Immunoregulation by Resveratrol; Implications for Normal Tissue Protection and Tumour Suppression, Clinical and Experimental Pharmacology and Physiology (2023)
24. Evidence for the Benefits of Melatonin in Cardiovascular Disease, Frontiers in Cardiovascular Medicine (2022)
25. Chemotherapy: A Double-Edged Sword in Cancer Treatment, Cancer Immunology# Immunotherapy (2022)